Theranostics of Metastatic Prostate Cancer Applying ⁶⁴Cu/¹⁸F/⁶⁸Ga PSMA PET-CT and ¹⁷⁷Lu Radiopharmaceuticals

Title:Theranostics of Metastatic Prostate Cancer Applying ⁶⁴Cu/¹⁸F/⁶⁸Ga PSMA PET-CT and ¹⁷⁷Lu Radiopharmaceuticals

Volume: 14 Issue: 4

Author(s): Siroos Mirzaei*, Fairoz Mohammed and Shahin Zandieh

Affiliation:

• Department of Nuclear Medicine with PET-Center, Wilhelminenspital, Vienna,Austria

Keywords: Peptide radioligand therapy, ⁶⁴CuCl₂, CRPC, PET-CT, NET, prostate cancer, glioblastoma, melanoma.

Abstract: The successful use of theranostic twins in neuroendocrine tumors (NET) is the pioneering approach to radionuclide therapy in other tumor types. ⁶⁴Cu/¹⁸F PSMA for molecular imaging with PET-CT and peptide radioligand therapy (PRLT) with 177Lu labeled PSMA inhibitors are the next theranostic twins in nuclear medicine. ⁶⁸Ga/ ⁶⁴Cu/¹⁸F PSMA PET-CT detects metastatic prostate cancer with high diagnostic sensitivity and specificity and can be used to select patients for PRLT and evaluate therapy response. Radionuclide therapy with ¹⁷⁷Lu-PSMA inhibitors has been shown to be effective in the treatment of metastatic CRPC.

Cite this article as:

Mirzaei Siroos *, Mohammed Fairoz and Zandieh Shahin, Theranostics of Metastatic Prostate Cancer Applying ⁶⁴Cu/¹⁸F/⁶⁸Ga PSMA PET-CT and ¹⁷⁷Lu Radiopharmaceuticals, Current Radiopharmaceuticals 2021; 14 (4) . https://dx.doi.org/10.2174/1874471013666200908122845